Félicie Lorenc

Félicie joined the Hallegger Group and the Oxford-GSK Institute of Molecular and Computational Medicine in November 2025 as a Postdoctoral Research Scientist. Her research focuses on the role of RNA-binding proteins in the disease continuum linking amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

She is developing human iPSC-derived neuronal models to investigate early pathological mechanisms underlying ALS. This work builds on recent findings showing that the condensation of TDP-43, a protein centrally implicated in ALS and FTD, alters its binding to and processing of specific RNAs. By using ALS-causing mutations to manipulate TDP-43 condensation in human neurons, she aims to determine how these changes affect neuronal health and transcriptomic profiles, combining advanced microscopy and integrative transcriptomic approaches.

Prior to joining Oxford, Félicie obtained a Bachelor's degree in Life Sciences in 2017 and an interdisciplinary Master's degree in Neurobiology and Neuroscience in 2020 from the École Normale Supérieure (Paris, France). She then completed her PhD in Neuroscience at the University of Strasbourg (France) in 2024, where she developed novel mouse models to investigate the contribution of inhibitory neurons to ALS and FTD. Her doctoral research focused on motor and social phenotypes associated with FUS protein.